No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
ITRM Iterum Therapeutics
- 1.5500
- -0.0300-1.90%
Close May 3 16:00 ET
- 1.5700
- +0.0200+1.29%
Post 16:08 ET
25.66MMarket Cap-523P/E (TTM)
1.6300High1.5200Low46.92KVolume1.5800Open1.5800Pre Close73.84KTurnover0.30%Turnover RatioLossP/E (Static)16.55MShares2.500052wk High-4.01P/B23.97MFloat Cap0.622052wk Low--Dividend TTM15.46MShs Float195.0000Historical High--Div YieldTTM6.96%Amplitude0.6010Historical Low1.5730Avg Price1Lot Size
Full Hours
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
HC Wainwright & Co. : The Iterum Therapeutics (ITRM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
HC Wainwright & Co. : The Iterum Therapeutics (ITRM.US) rating was reaffirmed and adjusted from buy to buy, with a target price of $6.00.
Analysts Are Bullish on Top Healthcare Stocks: Abbott Labs (ABT), Iterum Therapeutics (ITRM)
Iterum Therapeutics Resubmits New Drug Application To FDA For Oral Sulopenem
Iterum Therapeutics Resubmits New Drug Application To FDA For Oral Sulopenem
PERI, ITRM and CADL Among Pre-market Losers
On April 3, Iterum Therapeutics Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule
On April 3, Iterum Therapeutics Received Letter From Nasdaq Indicating That It Is Not In Compliance With Nasdaq Listing Rule
Analysts Offer Insights on Healthcare Companies: CalciMedica (CALC), Apollomics (APLM) and Iterum Therapeutics (ITRM)
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg